War, supply chains, and the case for Africa’s pharmaceutical manufacturing

Global supply chain vulnerabilities have become unmistakable. International conflicts—from Eastern Europe to the Middle East—are disrupting the flow of essential medicines, APIs (active pharmaceutical ingredients), and manufacturing equipment across traditional trade routes. For European investors seeking resilience and returns, Africa's pharmaceutical manufacturing sector now presents a compelling counterweight to Western supply chain concentration.

The reality is stark: approximately 80% of global API production remains concentrated in China and India, with manufacturing hubs vulnerable to geopolitical shocks, tariffs, and logistical interruptions. When wars disrupt shipping lanes or trigger sanctions regimes, European hospitals and clinics face medicine shortages. This fragility has exposed a critical strategic gap: Western nations lack domestic pharmaceutical redundancy.

Kenya, Nigeria, South Africa, and Egypt are rapidly filling this void. Kenya's pharmaceutical manufacturing sector has grown 12% annually over the past five years, with over 100 licensed manufacturers now producing everything from antibiotics to antimalarials. The country benefits from East African Community trade advantages, English-language governance frameworks familiar to European operators, and a skilled technical workforce. Nigeria's pharmaceutical market—valued at $3.2 billion—is increasingly vertically integrated, with local manufacturers moving upstream into API production. South Africa remains the continent's most mature hub, hosting facilities that already export to Europe under strict regulatory compliance.

For European entrepreneurs and investors, this creates multiple value propositions:

**Supply Chain Diversification.** Establishing or acquiring African pharmaceutical manufacturing capacity reduces exposure to Asian bottlenecks. A mid-sized European pharmaceutical company can establish a production facility in Kenya or South Africa for €8–15 million, capturing tariff benefits under EU-Africa trade agreements while securing 3–5 year payback periods through API exports back to Europe.

**Regulatory Arbitrage.** African manufacturers increasingly meet EU Good Manufacturing Practice (GMP) standards. South African facilities already export to the EU; Kenya and Nigeria are following. This means European companies can access lower labor costs (40–60% below EU wages) while maintaining quality compliance—a competitive advantage in generics and over-the-counter segments.

**Currency and Macro Tailwinds.** Africa's growing middle class is driving domestic pharmaceutical demand at 7–9% CAGR, far outpacing European growth rates of 2–3%. Investing in manufacturing capacity captures both export revenue *and* growing local market penetration.

**Geopolitical Insurance.** Owning production capacity on the African continent insulates European supply chains from Chinese export restrictions, Indian regulatory actions, or shipping disruptions. This insurance premium is increasingly valuable.

The risks are real: currency volatility, regulatory inconsistency across borders, and infrastructure gaps in some regions. But these are manageable through structured partnerships with local co-investors and technology transfer arrangements.

The window is open, but not indefinitely. As African governments strengthen IP protections and manufacturers scale capacity, valuations will rise. Early-mover European investors can establish footholds now at favorable entry prices before the sector becomes mainstream and capital competes margins down.

---

#